Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
1 hedge funds and large institutions have $1K invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 14 closing their positions.
7.94% less ownership
Funds ownership: 7.95% → 0.02% (-7.9%)
93% less funds holding
Funds holding: 15 → 1 (-14)
100% less capital invested
Capital invested by funds: $456K → $1K (-$455K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 14
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JC
JBF Capital
Aspen,
Colorado
|
-$286K |
| 2 |
GS
GTS Securities
Miami,
Florida
|
-$48.6K |
| 3 |
VF
Virtu Financial
New York
|
-$42K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$40.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$22.4K |
FRTX Hedge Fund Activity: Q4 2023 in Review
1 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q4 2023, worth a combined $1K — down 100% from $456K a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of FRTX and 0 opened new positions — a net loss of 14 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was JBF Capital, exiting entirely with an estimated $286K sold.
- 1 institutional investor held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q4 2023, down from 15 in Q3 2023.
- Funds reported $1K of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q4 2023 and 14 closed out, a net change of -14 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q4 2023 was JBF Capital, an estimated $286K sold.
Based on aggregated 13F filings for Q4 2023.